Physician profile
Lynn M Chen
NPI 1538698691
$6,599.98
in general payments reported to CMS, 2019-2025
31 companies · $2,237 in 2025
The $2,237 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $502 · 2022: $1,333 · 2023: $1,311 · 2024: $1,217 · 2025: $2,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,765.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,417.16 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $510.59 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $492.10 | 2025 | Tremfya |
| Evoke Pharma, INC. | $327.96 | 2022-2025 | Gimoti |
| Lilly USA, LLC | $282.02 | 2024-2025 | Omvoh |
| Novo Nordisk INC | $241.13 | 2022-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.67 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Scientific Affairs, LLC | $220.26 | 2022-2023 | Stelara |
| Regeneron Healthcare Solutions, INC. | $185.73 | 2023-2025 | Dupixent |
| Biohaven Pharmaceuticals, INC. | $166.97 | 2021 | |
| Genzyme Corporation | $164.42 | 2022-2025 | |
| Catalyst Pharmaceuticals, INC. | $163.10 | 2023 | Firdapse |
| Gilead Sciences, INC. | $150.74 | 2025 | Livdelzi |
| Madrigal Pharmaceuticals | $132.71 | 2025 | Rezdiffra |
| Qol Medical, LLC | $128.91 | 2024-2025 | Sucraid, Sucraid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $126.23 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $112.45 | 2024-2025 | Entyvio, Eohilia |
| Biohaven Pharmaceutical Holding Company LTD. | $110.78 | 2022 | |
| Neurocrine Biosciences, INC. | $108.29 | 2022 | |
| Paratek Pharmaceuticals, INC. | $100.49 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $39.43 | 2022 | |
| Genentech USA, INC. | $29.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.00 | 2022 | |
| Braintree Laboratories, INC. | $22.36 | 2025 | Suflave |
| Intercept Pharmaceuticals, INC. | $19.28 | 2025 | |
| Ardelyx, INC. | $18.34 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $17.65 | 2025 | |
| Organon LLC | $17.34 | 2025 | Hadlima, Renflexis |
| Ipsen Biopharmaceuticals, INC | $17.04 | 2025 | Iqirvo |
| Celgene Corporation | $15.71 | 2023 | Zeposia |
| Redhill Biopharma INC. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.